Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors. Part Two of this study will determine the safety of TIL therapy with lymphodepleting chemotherapy and post-TIL Interleukin-2 in high-risk pediatric solid tumors

See also
Status	Clinical Trial	Phase
Completed	`NCT03336086` - Effect of Weight Reduction on Immunity	Phase 3
Withdrawn	`NCT00514982` - Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome	Phase 2
Completed	`NCT05506748` - Association Between Preoperative HALP and Immediate Postoperative Outcomes

NCT number	NCT06047977
Study type	Interventional
Source	Johns Hopkins All Children's Hospital
Contact	Jade Hanson
Phone	7277676468
Email	jade.hanson@jhmi.edu
Status	Not yet recruiting
Phase	Phase 1
Start date	October 1, 2024
Completion date	December 1, 2027

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms